The program, designed to stem the growing prevalence of obesity in
Leveraging our strong partnerships, we offer a range of GLP-1 medications directly sourced from the leading pharmaceutical innovators, said
We've negotiated competitive pricing with these leading pharmaceutical manufacturers, allowing us to offer these original GLP-1 medications at pricing starting at less than
Co-CEO Dr.
Marketed with the tagline, "It's Okay to Not Be Okay," the MaNaDr program is among the few of its kind in the APAC region to offer a one-stop source for patients weight management needs. Services provided include:
Medical Intervention. Patients can consult with doctors for personalized medical advice, including the suitability of using GLP-1 medications such as Semaglutide (brand names Wegovy and Rybelsus), Liraglutide (Saxenda), Dulaglutide (Trucility), or other prescription weight loss medications.
Mental/Emotional Support. Patients receive ongoing mental and emotional support from a dedicated personal care consultant and coach, who will set achievable goals, guide them through challenges, and celebrate their successes.
Nutritional Guidance. Patients can work with registered dietitians to develop a personalized, sustainable eating plan.
Fitness Expertise. Patients can consult with certified exercise instructors to create an exercise program that fits their needs and preferences.
24/7 Availability. Patients can contact a member of their healthcare team to discuss immediate concerns around the clock.
Data-Driven Tracking. Patients can track their progress with a user-friendly personal lifestyle diary that monitors meals, physical activity, and body measurements.
Effortless Refills. Patients can refill their prescriptions quickly and easily within the MaNaDr app.
In-Clinic Option. Patients preferring in-person visits may schedule them and receive comprehensive physical evaluations.
Many weight management solutions available today ultimately fail partly because patients do not receive the help they need, when they need it, said MaNaDr co-CEO Dr.
"Several recent studies demonstrate that GLP-1 medications like Saxenda can help most patients lose five to ten percent of their body weight within a reasonable period of time," stated
Equally important, she added, is the availability of professional mental health support for weight management patients. Often underestimated, and even overlooked, is the fear, isolation, cravings, and shame experienced by many patients with weight management issues. We address these needs by making certain that patients have a dedicated personal care consultant and coach who is thoroughly familiar with a patients needs, and by making a professional available to consult with patients on a 24/7 basis. No patient in our program will ever have their needs ignored when they need help.
Thirdly,
MaNaDr co-CEO Dr.
About
Ranked #41 in the
Considering GLP-1 medications for weight management? Learn more about this option and explore if it's right for you. Visit our website https://manadr.com/weight-management or schedule a convenient teleconsultation with our specialist doctors through the MaNaDr app.
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Companys expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Companys ability to execute our strategies, manage growth and maintain our corporate culture; the Companys future business development, financial conditions and results of operations; expectations regarding demand for and market acceptance of our products and services; changes in technology; economic conditions; the growth of the telehealth solutions industry in
For media inquiries, please contact:
Mobile-health Network Solutions Investor Relations Contact:
(+65) 6222 5223
Email: investors@manadr.com
Investor Relations Inquiries:
Office: (646) 893-5835
Email: info@skylineccg.com
Copyright 2024 JCN Newswire . All rights reserved.
© Japan Corporate News, source